Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) shares fell 1.6% during mid-day trading on Monday . The company traded as low as $3.67 and last traded at $3.72, with a volume of 222,500 shares trading hands. The stock had previously closed at $3.78.

A number of research firms recently issued reports on TTPH. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Wednesday, July 6th. Gabelli downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 target price on the stock. in a research report on Friday, May 13th. Wedbush dropped their target price on shares of Tetraphase Pharmaceuticals from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, May 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Saturday, May 14th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and an average target price of $14.85.

The stock has a 50 day moving average of $4.03 and a 200-day moving average of $4.36. The stock’s market capitalization is $136.52 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.01. During the same quarter last year, the company earned ($0.72) EPS. The firm had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $2.05 million. The business’s revenue was down 63.6% on a year-over-year basis. Equities research analysts expect that Tetraphase Pharmaceuticals Inc. will post ($1.98) earnings per share for the current year.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.